Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succeeds Elisabet de los Pinos, Ph.D., the Company’s founder,…

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of…

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants…

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 05, 2026 (GLOBE NEWSWIRE)  Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in…

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

BOSTON, May 11, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial…

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026. Fireside Chat at 12:00 p.m. ET TD Cowen 7th Annual…

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura’s new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are…

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the…

Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG

April 2, 2026 POLAR is a randomized, double-blind, placebo-controlled study that enrolled 43 patients with PMM2-CDG across 15 sites globally with topline data expected in the fourth quarter of 2026 Primary endpoint evaluates change in ataxia at 24 weeks, as measured by the International Cooperative Ataxia Rating Scale (ICARS) SAN CARLOS, Calif., April 2, 2026…

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

May 11, 2026 PDF Version Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ:…